Literature DB >> 11563251

Typhoid vaccines.

A Aggarwal1, A K Dutta.   

Abstract

Typhoid fever continues to be a major public health problem in developing countries with about 33 million cases per year. Protective efficacy of traditional acetone/phenol killed vaccines is similar to newer typhoid vaccines (Ty21A and Vi antigen vaccine) but side effects of these newer vaccines are considerably less. Though the mortality is low, typhoid fever causes considerable morbidity and loss of working days. Problems during treatment are increasing due to emergence and spread of multidrug resistant S. typhi. Hence to decrease the incidence of typhoid fever in addition to ensuring safe water supply and excreta disposal a typhoid vaccine needs to be introduced in the National Immunization Schedule.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11563251     DOI: 10.1007/bf02752413

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  23 in total

1.  Multidrug-resistant typhoid in children: presentation and clinical features.

Authors:  Z A Bhutta; S H Naqvi; R A Razzaq; B J Farooqui
Journal:  Rev Infect Dis       Date:  1991 Sep-Oct

2.  Epidemic multiresistant enteric fever in eastern India.

Authors:  A C Anand; V K Kataria; W Singh; S K Chatterjee
Journal:  Lancet       Date:  1990-02-10       Impact factor: 79.321

3.  Summary of an international workshop on typhoid fever.

Authors:  R Edelman; M M Levine
Journal:  Rev Infect Dis       Date:  1986 May-Jun

4.  A controlled field trial and laboratory study of five typhoid vaccines in the USSR.

Authors:  L B Hejfec; L V Salmin; M Z Lejtman; M L Kuz'minova; A V Vasil'eva; L A Levina; T G Bencianova; E A Pavlova; A A Antonova
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

5.  Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.

Authors:  K P Klugman; I T Gilbertson; H J Koornhof; J B Robbins; R Schneerson; D Schulz; M Cadoz; J Armand
Journal:  Lancet       Date:  1987-11-21       Impact factor: 79.321

6.  Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine.

Authors:  R Germanier; E Füer
Journal:  J Infect Dis       Date:  1975-05       Impact factor: 5.226

7.  Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya.

Authors:  N B Mirza; I A Wamola; B A Estambale; E Mbithi; M Poillet
Journal:  East Afr Med J       Date:  1995-03

8.  Typhoid fever in children aged less than 5 years.

Authors:  A Sinha; S Sazawal; R Kumar; S Sood; V P Reddaiah; B Singh; M Rao; A Naficy; J D Clemens; M K Bhan
Journal:  Lancet       Date:  1999-08-28       Impact factor: 79.321

Review 9.  Salmonella-based vaccines.

Authors:  J Hackett
Journal:  Vaccine       Date:  1990-02       Impact factor: 3.641

10.  Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.

Authors:  S C Szu; A L Stone; J D Robbins; R Schneerson; J B Robbins
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.